Patents Assigned to Beth Israel Deaconess Medical Center, Inc.
  • Publication number: 20210052598
    Abstract: The present disclosure features compositions and methods of treating a cancer in a subject by administering to the subject a Skp2 inhibitor and an inhibitor of glycolytic metabolism (e.g., PKM2 inhibitor).
    Type: Application
    Filed: March 6, 2019
    Publication date: February 25, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Wenyi Wei
  • Patent number: 10898100
    Abstract: Electrical impedance myography (EIM) can be used for the assessment and diagnosis of muscular disorders. EIM includes applying an electrical signal to a region of tissue and measuring a resulting signal. A characteristic of the region of tissue is determined based on the measurement. Performing EIM at different frequencies and/or different angular orientations with respect to a muscle can aid in the assessment and diagnosis. Devices are described that facilitate assessment and diagnosis using EIM.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: January 26, 2021
    Assignees: Beth Israel Deaconess Medical Center, Inc., Northeastern University
    Inventors: Seward B. Rutkove, Carl A. Shiffman, Ronald Aaron
  • Publication number: 20210002649
    Abstract: The invention generally provides a method of treating cancer, the method comprising administering to a subject having a cancer, an effective amount of an agent that inhibits the expression or activity of WW domain-containing protein-1 (WWP1) in combination with anti-PD-1 and/or anti-PD-L1 monoclonal antibodies.
    Type: Application
    Filed: February 28, 2019
    Publication date: January 7, 2021
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Wenyi Wei, Pier Paolo Pandolfi, Yu Ru Lee
  • Patent number: 10884001
    Abstract: Featured are methods of diagnosing and treating liver disease.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 5, 2021
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Detlef Schuppan, Towia Libermann, Simon T. Dillon, Yury Papou
  • Publication number: 20200377576
    Abstract: Disclosed herein are methods and compositions for treating a subject having or at risk of having an HIV infection. Disclosed herein are peptide immunogens and nucleic acids that have epitopes in which mutations are most likely to have deleterious effects on the HIV virus. An algorithm is disclosed for the selection of the epitopes based on the HIV fitness landscape, and it accounts for the effect of coupling mutations.
    Type: Application
    Filed: May 29, 2020
    Publication date: December 3, 2020
    Applicants: Massachusetts Institute of Technology, The General Hospital Corporation, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Darrell J. Irvine, Dan H. Barouch, Arup K. Chakraborty, Dariusz Murakowski, Bruce D. Walker, John Barton, Andrew Ferguson
  • Publication number: 20200375480
    Abstract: Disclosed herein are example methods and systems for non-invasive cardiovascular risk assessment using heart rate variability fragmentation. A first set of electrocardiogram (ECG) signals may be received from a subject. Data from the first set of ECG signals may be analyzed to identify sign changes in heart rate acceleration in the first set of ECG signals. Based on the identified sign changes in heart rate acceleration, a degree of fragmentation in the first set of ECG signals may be determined. Afterwards, cardiovascular risk of the subject may be assessed based on the degree of fragmentation.
    Type: Application
    Filed: March 23, 2018
    Publication date: December 3, 2020
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventors: Madalena D. COSTA, Ary L. GOLDBERGER
  • Publication number: 20200377599
    Abstract: Provided are compositions and methods of treating subjects having cancer which involve administering to the subject an anti-PD-L1 or an anti-PD-1 antibody and an inhibitor of cyclin D kinase (CDK)4/6 to treat the cancer. Combining CDK4/6 inhibitor treatment with anti-PD-L1 or anti-PD-1 immunotherapy enhanced tumor regression and dramatically improved overall survival rates in tumor models.
    Type: Application
    Filed: November 28, 2018
    Publication date: December 3, 2020
    Applicant: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventor: WENYI WEI
  • Publication number: 20200352443
    Abstract: Methods and apparatus for providing a functional mapping of a brain lesion in a patient's brain. The method comprises determining using a computer processor, based on human connectome data stored on at least one computer datastore in communication with the computer processor, at least one functional network associated with a location of a brain lesion identified in an image of a patient's brain. The at least one functional network includes a plurality of brain areas functionally connected to the location of the brain lesion and a plurality of correlation measures. Each of the correlation measures indicates a strength of functional connection between the location of the brain lesion and a respective brain area of the plurality of brain areas in the at least one functional network. The method further comprises determining, based at least one functional network, a likelihood that the brain lesion is causing one or more patient symptoms.
    Type: Application
    Filed: July 28, 2017
    Publication date: November 12, 2020
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Michael D. Fox
  • Patent number: 10806890
    Abstract: Apparatus and methods for producing narrow-band radiation in the green region of the visible spectrum are described. The narrow-band radiation may be used to aid subjects experiencing photophobia. In some cases, subjects may experience a reduction in pain (e.g., migraine photophobia) when using the narrow-band radiation.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: October 20, 2020
    Assignee: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
    Inventor: Rami Burstein
  • Publication number: 20200308538
    Abstract: The invention features compositions and methods that are useful for generating human hepatocyte-like cells (HLCs) and methods of using such cells for the treatment of diseases associated with a loss in liver cell number or function.
    Type: Application
    Filed: September 10, 2018
    Publication date: October 1, 2020
    Applicants: BETH ISRAEL DEACONESS MEDICAL CENTER, INC., VIRGINIA COMMONWEALTH UNIVERSITY
    Inventors: ROBERT A. FISHER, GIUSEPPE PETTINATO
  • Patent number: 10788555
    Abstract: A magnetic resonance imaging (MRI) system is provided that is controlled by a computer. The computer is programmed to control a plurality of gradient coils and radio frequency (RF) system of the MRI system to perform at least one pulse sequence that includes applying RF energy at least at two frequencies to manipulate exchangeable magnetization from protons in a subject. The computer is also programmed to control the plurality of gradient coils and RF system to acquire imaging data including magnetization transfer information from the exchangeable magnetization from protons in the subject in response to the pulse sequence. The computer is further programmed to, using frequency information associated with the imaging data, generate a report pertaining to inhomogeneous magnetization transfer occurring in the subject in response to the pulse sequence.
    Type: Grant
    Filed: March 11, 2019
    Date of Patent: September 29, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: David Alsop, Gopal Varma
  • Publication number: 20200297235
    Abstract: Described herein are embodiments of methods and apparatus for diagnosing neuromuscular diseases using an impedance-EMG needle, and for generating electrical impedance images using an impedance needle. Some embodiments provide an apparatus including an impedance-EMG needle, including both EMG electrodes and impedance electrodes, to measure both active and passive electrical properties of muscle. Other embodiments provide an apparatus including an impedance needle, including a plurality of impedance electrodes to measure impedance in tissue surrounding the impedance needle to generate an electrical impedance image. Use of such methods and apparatus may be advantageous in improving the accuracy of assessing and diagnosing neuromuscular disease.
    Type: Application
    Filed: May 16, 2018
    Publication date: September 24, 2020
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Benjamin Sanchez, Seward B. Rutkove, Hyeuknam Kwon
  • Publication number: 20200297266
    Abstract: Described herein are embodiments of an approach to diagnosing pancreatic cystic lesions using light scattering spectroscopy. In some embodiments, the approach includes an apparatus including a spatial gating probe to isolate light reflected by the epithelial tissue of the internal cyst surface using spatial gating. In some further embodiments, the apparatus includes a scanning fiber probe that is capable of rotational and linear motion in order to scan the entire internal surface of the cyst. Use of such an approach may be advantageous to improve the accuracy of diagnosing pancreatic cystic lesions as cancerous, precancerous, or benign.
    Type: Application
    Filed: February 23, 2018
    Publication date: September 24, 2020
    Applicant: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Lev T. Perelman
  • Patent number: 10781248
    Abstract: The specification provides compositions comprising chimeric proteins comprising AAT conjugated to an Fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., Type 1 and Type 2 diabetes, are also provided.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: September 22, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Terry B. Strom, Maria Koulmanda
  • Patent number: 10781427
    Abstract: The present invention relates to recombinant adenoviruses and vectors thereof. In particular, the adenoviruses are novel simian adenoviruses having a low seroprevalence and high immunogenicity relative to other adenoviruses and vectors thereof. The invention also provides methods for production of the adenoviruses and for the treatment of diseases by administering the adenoviral vector(s) to a subject (e.g., a human).
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 22, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Washington University
    Inventors: Dan H. Barouch, Herbert Virgin, IV, Peter Abbink
  • Patent number: 10772952
    Abstract: The invention provides compositions, methods, and kits for the treatment or prevention of viral infections. The polyvalent (e.g., 2-valent) vaccines described herein incorporate computationally-optimized viral polypeptides that can increase the diversity or breadth and depth of cellular immune response in vaccinated subjects.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 15, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Triad National Security, LLC
    Inventors: Dan H. Barouch, Bette T. Korber, William M. Fischer
  • Patent number: 10772974
    Abstract: The invention relates to the use of a CITED4 polypeptide and/or a microRNA-222 or precursor (e.g., pre-miR-222) or mimic thereof, for treating a cardiovascular disease or pathological condition, such as heart failure, myocardial infarction, and for promoting post-myocardial infarction cardiac remodeling in heart tissue.
    Type: Grant
    Filed: November 18, 2014
    Date of Patent: September 15, 2020
    Assignees: Beth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
    Inventors: Anthony Rosenzweig, Vassilios J. Bezzerides
  • Patent number: 10766952
    Abstract: The present invention relates to methods for selecting a headache patient responsive to treatment with an anti-CGRP antibody and to methods for reducing headache frequency in the selected patient comprising administering an anti-CGRP antibody.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: September 8, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventor: Rami Burstein
  • Patent number: 10745479
    Abstract: This present invention relates to compounds (e.g., TM4SF1 binding proteins, e.g., anti-TM4SF1 antibodies) that specifically bind to a polypeptide at an epitope including an amino acid sequence of SEQ ID NO: 1. In particular, the compounds of the invention are capable of being internalized into a TM4SF1-expressing cell (e.g., a tumor cell or an angiogenic vasculature endothelial cell) following binding to the epitope of including the amino acid sequence of SEQ ID NO: 1. The invention also provides methods of treating a subject having a disorder associated with pathological angiogenesis with the compounds of the invention.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: August 18, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Shou-Ching S. Jaminet, Harold F. Dvorak
  • Publication number: 20200255831
    Abstract: Methods for diagnosis and treatment of cancers by use of exosomes comprising miRNAs and precursors thereof. For example, in some aspects, a cancer may be diagnosed or evaluated by determining the miRNA content of exosomes in a sample from a subject or by detecting miRNA processing in exosomes.
    Type: Application
    Filed: March 23, 2020
    Publication date: August 13, 2020
    Applicants: Board of Regents, The University of Texas System, Beth Israel Deaconess Medical Center, Inc.
    Inventors: Raghu KALLURI, Sónia MELO